| Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids KK Dijkstra, CM Cattaneo, F Weeber, M Chalabi, J van de Haar, ... Cell 174 (6), 1586-1598. e12, 2018 | 951 | 2018 |
| Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients SN Ooft, F Weeber, KK Dijkstra, CM McLean, S Kaing, E van Werkhoven, ... Science translational medicine 11 (513), eaay2574, 2019 | 628 | 2019 |
| Caring for patients with cancer in the COVID-19 era J van de Haar, LR Hoes, CE Coles, K Seamon, S Fröhling, D Jäger, ... Nature medicine 26 (5), 665-671, 2020 | 402 | 2020 |
| MHC-I genotype restricts the oncogenic mutational landscape R Marty, S Kaabinejadian, D Rossell, MJ Slifker, J van de Haar, HB Engin, ... Cell 171 (6), 1272-1283. e15, 2017 | 355 | 2017 |
| γδ T cells are effectors of immunotherapy in cancers with HLA class I defects NL de Vries, J van de Haar, V Veninga, M Chalabi, ME Ijsselsteijn, ... Nature 613 (7945), 743-750, 2023 | 175 | 2023 |
| Prospective experimental treatment of colorectal cancer patients based on organoid drug responses SN Ooft, F Weeber, L Schipper, KK Dijkstra, CM McLean, S Kaing, ... ESMO open 6 (3), 100103, 2021 | 104 | 2021 |
| Identifying epistasis in cancer genomes: a delicate affair J van de Haar, S Canisius, KY Michael, EE Voest, LFA Wessels, T Ideker Cell 177 (6), 1375-1383, 2019 | 98 | 2019 |
| Limited evolution of the actionable metastatic cancer genome under therapeutic pressure J van de Haar, LR Hoes, P Roepman, MP Lolkema, HMW Verheul, ... Nature Medicine 27 (9), 1553-1563, 2021 | 61 | 2021 |
| Functional precision oncology using patient-derived assays: bridging genotype and phenotype AWJ van Renterghem, J van de Haar, EE Voest Nature Reviews Clinical Oncology 20 (5), 305-317, 2023 | 57 | 2023 |
| Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer J van de Haar, X Ma, SN Ooft, PW van der Helm, LR Hoes, S Mainardi, ... Nature Medicine 29 (3), 605-614, 2023 | 56 | 2023 |
| Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial YL Verschoor, J van de Haar, JG van den Berg, JW van Sandick, ... Nature medicine 30 (2), 519-530, 2024 | 47 | 2024 |
| Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment LR Hoes, JM van Berge Henegouwen, H van der Wijngaart, LJ Zeverijn, ... Clinical Cancer Research 28 (7), 1402-1411, 2022 | 46 | 2022 |
| A pan-cancer analysis of the microbiome in metastatic cancer TW Battaglia, IL Mimpen, JJH Traets, A van Hoeck, LJ Zeverijn, BS Geurts, ... Cell 187 (9), 2324-2335. e19, 2024 | 40 | 2024 |
| Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine J van de Haar, L Hoes, E Voest Esmo Open 4 (2), 2019 | 31 | 2019 |
| Patient-derived organoid models of human neuroendocrine carcinoma KK Dijkstra, JG Van den Berg, F Weeber, J Van de Haar, A Velds, S Kaing, ... Frontiers in endocrinology 12, 627819, 2021 | 30 | 2021 |
| Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer J van de Haar, JM Mankor, K Hummelink, K Monkhorst, EF Smit, ... Clinical Cancer Research 30 (7), 1307-1318, 2024 | 11 | 2024 |
| Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma LVM Leek, JCL Notohardjo, K de Joode, EL Velker, JBAG Haanen, ... Scientific Reports 14 (1), 11244, 2024 | 4 | 2024 |
| Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort. B Geurts, LJ Zeverijn, TW Battaglia, J van de Haar, ... Journal of Clinical Oncology 41 (16_suppl), 2590-2590, 2023 | 4 | 2023 |
| 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study M Chalabi, YL Verschoor, J Van De Haar, J van den Berg, L Kodach, ... Annals of Oncology 33, S1106, 2022 | 4 | 2022 |
| γδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects NL de Vries, J van de Haar, V Veninga, M Chalabi, ME Ijsselsteijn, ... bioRxiv, 2021.10. 14.464229, 2021 | 4 | 2021 |
